[ICAM-1 and allergic inflammation].
Recent progress in the understanding of the physiopathology of asthma makes possible the revision of the objectives of treatment, to pass from short-term symptomatic control to a prolonged control of the illness. L'ICAM-1 is an excellent potential target for preventative treatment of asthma of viral origin. When there are agents available of both inhibiting histamine and positively regulating ICAM-1 there is no longer reason to use simple antihistamines.